Tags

Type your tag names separated by a space and hit enter

Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial.
Atherosclerosis. 2017 05; 260:1-7.A

Abstract

BACKGROUND AND AIMS

Elevated levels of lipoprotein(a) [Lp(a)] and oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) predict the progression of pre-existing mild-to-moderate calcific aortic valve stenosis (CAVS). Whether indirect markers of oxidation-specific epitopes (OSE) are also predictive is not known. The association between IgG and IgM autoantibodies and malondialdehyde-modified low density lipoprotein (MDA-LDL) and IgG and IgM apolipoprotein B immune complexes (apoB-IC), and the hemodynamic progression rate of CAVS was determined in the ASTRONOMER (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin, NCT00800800) trial.

METHODS

Plasma levels of IgG and IgM MDA-LDL and apoB-IC were measured in 220 patients with mild-to-moderate CAVS from the ASTRONOMER trial. The endpoint of this study was the progression rate of CAVS, measured by the annualized increase in peak aortic jet velocity (Vpeak) over a median follow-up of 3.5 [2.9-4.5] years.

RESULTS

There was no difference in the progression rate of CAVS across tertiles of IgG and IgM MDA-LDL and apoB-IC levels (all p > 0.05). After multivariable analysis, no marker reached significance level to predict faster CAVS progression or need for aortic valve replacement (all p > 0.05). There was no interaction between the OSE antibody titers and plasma levels of Lp(a) or OxPL-apoB, as well as age, with regards to the progression rate of CAVS.

CONCLUSIONS

Autoantibody titers to MDA-LDL and apoB-IC, which are an indirect measurement of OSE, unlike direct measurements of OxPL-apoB or their major lipoprotein carrier Lp(a), do not predict the progression of CAVS or need for AVR.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Capoulade R
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec Heart & Lung Institute, Laval University, Québec City, Québec, Canada.
Chan KL
University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Mathieu P
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec Heart & Lung Institute, Laval University, Québec City, Québec, Canada.
Bossé Y
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec Heart & Lung Institute, Laval University, Québec City, Québec, Canada.
Dumesnil JG
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec Heart & Lung Institute, Laval University, Québec City, Québec, Canada.
Tam JW
St. Boniface General Hospital, Winnipeg, Manitoba, Canada.
Teo KK
McMaster University, Hamilton, Ontario, Canada.
Yang X
University of California San Diego, La Jolla, CA, USA.
Witztum JL
University of California San Diego, La Jolla, CA, USA.
Arsenault BJ
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec Heart & Lung Institute, Laval University, Québec City, Québec, Canada.
Després JP
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec Heart & Lung Institute, Laval University, Québec City, Québec, Canada.
Pibarot P
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec Heart & Lung Institute, Laval University, Québec City, Québec, Canada. Electronic address: philippe.pibarot@med.ulaval.ca.
Tsimikas S
University of California San Diego, La Jolla, CA, USA. Electronic address: stsimikas@ucsd.edu.

MeSH

AdolescentAdultAgedAged, 80 and overAntibodies, Anti-IdiotypicAortic ValveAortic Valve StenosisAutoantibodiesBiomarkersCalcinosisDisease ProgressionDose-Response Relationship, DrugEpitopesFemaleFollow-Up StudiesHumansImmunoglobulin GMaleMiddle AgedOxidation-ReductionRetrospective StudiesRosuvastatin CalciumTime FactorsYoung Adult

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

28319871

Clinical Trial Links

Clinical trial which this article describes

Citation

Capoulade, Romain, et al. "Autoantibodies and Immune Complexes to Oxidation-specific Epitopes and Progression of Aortic Stenosis: Results From the ASTRONOMER Trial." Atherosclerosis, vol. 260, 2017, pp. 1-7.
Capoulade R, Chan KL, Mathieu P, et al. Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial. Atherosclerosis. 2017;260:1-7.
Capoulade, R., Chan, K. L., Mathieu, P., Bossé, Y., Dumesnil, J. G., Tam, J. W., Teo, K. K., Yang, X., Witztum, J. L., Arsenault, B. J., Després, J. P., Pibarot, P., & Tsimikas, S. (2017). Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial. Atherosclerosis, 260, 1-7. https://doi.org/10.1016/j.atherosclerosis.2017.03.013
Capoulade R, et al. Autoantibodies and Immune Complexes to Oxidation-specific Epitopes and Progression of Aortic Stenosis: Results From the ASTRONOMER Trial. Atherosclerosis. 2017;260:1-7. PubMed PMID: 28319871.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial. AU - Capoulade,Romain, AU - Chan,Kwan L, AU - Mathieu,Patrick, AU - Bossé,Yohan, AU - Dumesnil,Jean G, AU - Tam,James W, AU - Teo,Koon K, AU - Yang,Xiaohong, AU - Witztum,Joseph L, AU - Arsenault,Benoit J, AU - Després,Jean-Pierre, AU - Pibarot,Philippe, AU - Tsimikas,Sotirios, Y1 - 2017/03/09/ PY - 2016/12/14/received PY - 2017/02/11/revised PY - 2017/03/08/accepted PY - 2017/3/21/pubmed PY - 2018/1/27/medline PY - 2017/3/21/entrez KW - Aortic stenosis KW - Calcific aortic valve stenosis KW - Doppler echocardiography KW - Lipoprotein(a) KW - Oxidation-specific biomarkers SP - 1 EP - 7 JF - Atherosclerosis JO - Atherosclerosis VL - 260 N2 - BACKGROUND AND AIMS: Elevated levels of lipoprotein(a) [Lp(a)] and oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) predict the progression of pre-existing mild-to-moderate calcific aortic valve stenosis (CAVS). Whether indirect markers of oxidation-specific epitopes (OSE) are also predictive is not known. The association between IgG and IgM autoantibodies and malondialdehyde-modified low density lipoprotein (MDA-LDL) and IgG and IgM apolipoprotein B immune complexes (apoB-IC), and the hemodynamic progression rate of CAVS was determined in the ASTRONOMER (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin, NCT00800800) trial. METHODS: Plasma levels of IgG and IgM MDA-LDL and apoB-IC were measured in 220 patients with mild-to-moderate CAVS from the ASTRONOMER trial. The endpoint of this study was the progression rate of CAVS, measured by the annualized increase in peak aortic jet velocity (Vpeak) over a median follow-up of 3.5 [2.9-4.5] years. RESULTS: There was no difference in the progression rate of CAVS across tertiles of IgG and IgM MDA-LDL and apoB-IC levels (all p > 0.05). After multivariable analysis, no marker reached significance level to predict faster CAVS progression or need for aortic valve replacement (all p > 0.05). There was no interaction between the OSE antibody titers and plasma levels of Lp(a) or OxPL-apoB, as well as age, with regards to the progression rate of CAVS. CONCLUSIONS: Autoantibody titers to MDA-LDL and apoB-IC, which are an indirect measurement of OSE, unlike direct measurements of OxPL-apoB or their major lipoprotein carrier Lp(a), do not predict the progression of CAVS or need for AVR. SN - 1879-1484 UR - https://www.unboundmedicine.com/medline/citation/28319871/Autoantibodies_and_immune_complexes_to_oxidation_specific_epitopes_and_progression_of_aortic_stenosis:_Results_from_the_ASTRONOMER_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0021-9150(17)30103-X DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓4 ↑1]

Related Citations

More